RxDoctor Payments Data

Wilbur Kuo, MD

Internal Medicine · Sykesville, MDNPI 1336118900

Payments from drug & device makers

$14,007in general payments, 2019–2025

Across 776 payments — averaging $18.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$1K
  • Novo Nordisk$1K
  • Pfizer$1K
  • Amgen$1K
  • GSK$778
  • plus $7K from 52 others

What the payments were for

  • Food & beverage$13,90499%
  • Education$1021%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)101$1,573
AstraZeneca69$1,415
Novo Nordisk81$1,201
Pfizer68$1,162
Amgen(2 entities)56$1,045
GSK52$778
Lilly USA, LLC42$719
Boehringer Ingelheim40$650
Johnson & Johnson21$584
Astellas Pharma US Inc17$444
Merck19$373
Antares Pharma, Inc.18$363
Takeda Pharmaceuticals U.S.A., Inc.18$325
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC18$293
Lundbeck LLC12$265
Amarin Pharma, Inc.14$264
Esperion Therapeutics, Inc.12$230
Exact Sciences7$187
Biohaven Pharmaceutical Holding Company Ltd.9$176
Teva Pharmaceuticals USA, Inc.10$171
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)6$158
Tolmar, Inc.8$124
Axsome Therapeutics, Inc.5$111
Radius Health, Inc.5$108
Bayer4$97
Jazz Pharmaceuticals Inc.5$89
Novartis5$85
Biohaven Pharmaceuticals, Inc.4$80
Dexcom, Inc.3$71
E.r. Squibb & Sons, L.L.C.3$66
Phathom Pharmaceuticals, Inc.4$59
Abbott3$55
Bausch Health US, LLC2$49
Neos Therapeutics, LP2$42
Seqirus USA Inc3$41
Xeris Pharmaceuticals, Inc.2$40
Nestle Healthcare Nutrition Inc.2$40
Grifols USA, LLC2$38
Eisai Inc.2$37
Idorsia Pharmaceuticals US Inc2$35
Inspire Medical Systems, Inc.1$35
Kaleo, Inc.2$34
Aerin Medical Inc.1$30
Sanofi Pasteur Inc.2$26
Sumitomo Pharma America, Inc.1$24
Paratek Pharmaceuticals, Inc.1$23
Upsher-smith Laboratories LLC1$21
Verity Pharmaceuticals Inc.1$20
Mallinckrodt Hospital Products Inc.1$20
Supernus Pharmaceuticals, Inc.1$19
Ironwood Pharmaceuticals, Inc1$16
Halozyme Inc1$16
Avanir Pharmaceuticals, Inc.1$15
Circassia Inc.1$15
Adlon Therapeutics L.p.1$15
Ironshore Pharmaceuticals Inc.1$14
Mylan Specialty L.p.1$12
Zyla Life Sciences, Inc.1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,007 in reported general payments places this provider in the 95th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$464,237
Medicare patients
585
Services billed
6,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban77$85,398
JardianceEmpagliflozin42$65,805
OzempicSemaglutide48$51,579
JanuviaSitagliptin Phosphate31$49,231
Trelegy ElliptaFluticasone/Umeclidin/Vilanter37$39,813
RybelsusSemaglutide25$37,892
Breo ElliptaFluticasone/Vilanterol40$31,342
XareltoRivaroxaban19$27,076
Tresiba Flextouch U-200Insulin Degludec19$24,766
MounjaroTirzepatide24$24,691
MyrbetriqMirabegron19$23,102
FarxigaDapagliflozin Propanediol14$22,609
ArexvyRsvpref3 Antigen/As01e/Pf35$10,942
Rosuvastatin Calcium168$5,440
Atorvastatin Calcium341$5,003

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,201$89,47173 claims
PfizerEliquis$1,162$85,39877 claims
GSKTrelegy Ellipta, Breo Ellipta, Arexvy, Shingrix$778$84,603123 claims
Boehringer IngelheimJardiance$650$65,80542 claims
MerckJanuvia$373$49,23131 claims
Johnson & JohnsonXarelto$584$27,07619 claims
Lilly USA, LLCMounjaro$719$24,69124 claims
Astellas Pharma US IncMyrbetriq$444$23,10219 claims
AstraZenecaFarxiga$1,415$22,60914 claims
AbbVieSynthroid$1,573$1,51917 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Sykesville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →